AbCellera Biologics Inc.

NasdaqGS:ABCL Stock Report

Market Cap: US$807.4m

AbCellera Biologics Future Growth

Future criteria checks 2/6

AbCellera Biologics's earnings are forecast to decline at 13.1% per annum while its annual revenue is expected to grow at 22.3% per year. EPS is expected to decline by 10.3% per annum.

Key information

-13.1%

Earnings growth rate

-10.3%

EPS growth rate

Life Sciences earnings growth18.1%
Revenue growth rate22.3%
Future return on equityn/a
Analyst coverage

Good

Last updated22 Aug 2024

Recent future growth updates

Recent updates

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

Earnings and Revenue Growth Forecasts

NasdaqGS:ABCL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202662-211N/AN/A5
12/31/202550-228N/AN/A9
12/31/202434-171N/AN/A10
6/30/202433-153-171-91N/A
3/31/202436-147-128-42N/A
12/31/202338-146-121-44N/A
9/30/202350-129-697N/A
6/30/2023145-74-189-120N/A
3/31/2023181-5060133N/A
12/31/2022485159205277N/A
9/30/2022603248160230N/A
6/30/2022507200287351N/A
3/31/2022489205166235N/A
12/31/2021375153186245N/A
9/30/2021444177212263N/A
6/30/2021448197219265N/A
3/31/2021431203120133N/A
12/31/202023385823N/A
9/30/2020280822N/A
6/30/20202321525N/A
3/31/202014-3-70N/A
12/31/201912-2-13N/A
12/31/201890-24N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABCL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABCL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABCL's revenue (22.3% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ABCL's revenue (22.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABCL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y